雷公藤多苷对白塞病患者血清细胞因子水平的影响

目的 探讨雷公藤多苷对白塞病患者血清细胞因子IL-4、IL-6、IL-8、IL-10水平的影响，进而从分子生物学水平探讨雷公藤多苷对白塞病的治疗作用及其可能的机制。方法 收集济宁医学院附属医院2007年6月至2009年6月门诊就诊的初治白塞病患者30例，给予雷公藤多苷片30 mg/d，疗程3个月，对照组为健康体检者30例。采用放免法测定白塞病患者接受雷公藤多苷治疗前后，以及对照组的血清细胞因子IL-4、IL-6、IL-8、IL-10的水平。并结合血沉、C-反应蛋白及临床表现等情况进行分析。结果 （1）白塞病患者治疗前血清IL-6、IL-8水平明显高于正常对照组（P＜0.05）， IL-4、IL-10水平较正常对照组无明显变化（P＞0.05）。（2）雷公藤多苷治疗3个月后患者血清IL-6、IL-8水平较治疗前明显减低（P＜0.05）， IL-4、IL-10水平较治疗前明显升高（P＜0.05）。（3）30例接受雷公藤多苷治疗的患者中，显效10例，有效16例，无效4例，有效率86.7%，治疗3个月后患者血沉、C-反应蛋白水平均较治疗前明显降低（P＜0.05）。结论 （1）白塞病患者血清IL-4、IL-6、IL-8、IL-10水平的失衡可能与其发病有关；（2）雷公藤多苷可有效调节白塞病患者血清IL-4、IL-6、IL-8、IL-10的水平，从而发挥其治疗作用。

Effect of Tripterygium Glycosides on serum IL-4,IL-6,IL-8,IL-10 in patients with Behcet's disease

Objective To investigate the serum levels of IL-4,IL-6,IL-8,IL-10 in Behcet′s disease （BD） patients before and after receiving the Tripterygium Glycosides therapy,and to explore the medication effect on Behcet′s disease,and the possible mechanism. Methods Collect serum from 30 initial patients,consulting to our clinics from 2007-6 to 2009-6,treated with oral Tripterygium Glycosides 30 mg/d,for 3 months.And 30 healthy yong man as control group.The serum levels of IL-4,IL-6,IL-8,IL-10 were detected by Radiation Immunosorbent Assay（RIA） respectively before and after the therapy.To analyse the result combined with the ESR,CRP and the clinical status of the patients. Results （1）Before the therapy, the levels of IL-6,IL-8 are evidently increased compared with the control group（P〈0.05）, the levels of IL-4,IL-10 showed no statistical significance compared with control group （P〉0.05）.（2）After 3 months Tripterygium Glycosides therapy,the levels of IL-6,IL-8 are evidently decreased compared with the levels before therapy （P〈0.05）,the level of IL-4,IL-10 increased compared with the therapy before （P〈0.05）.（3）In the 30 patients after Tripterygium Glycosides therapy,10 patients excellence,16 patients utility,and 4 patients ineffective,the effective rate is 86.6%,the level of ESR and CRP are evidently decreased compared with the levels before therapy （P〈0.05）. Conclusions （1）The unbalance of cellular factors IL-4,IL-6,IL-8,IL-10 in the BD patients may be related to the pathogenesis of BD （2）the Tripterygium Glycosides can treat the BD patients through effectively regulating the cellular factors IL-4,IL-6,IL-8,IL-10 in the BD patients serum.